Pharmacogenomics of Intergenic SNPs and in Silico Modeling for Precision Therapy

Technology #ua16-224

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Haiquan Li
Research Associate Professor, Medicine
Joanne Berghout
Research Assistant Professor, Medicine
Ikbel Achour
Director, Precision Health, Medicine
Yves Lussier
Associate Director, Medicine
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: Pharmacogenics of Intergenic SNPs and in Silico Modeling for Precision Therapy


Invention: A method for analyzing a single patient’s DNA and modeling how mutations and variations in intra-cell genomics will be expressed in the body. The information may be used to develop highly personalized therapies without the need for huge experimental data sets.


Background: Personalized medicine is the next frontier in therapeutics. Unfortunately, highly specific therapies are virtually incompatible with traditional research methods, which focus on generalized efficacy in cohort-level studies. Because of this, inventors at the University of Arizona sought to create a method that personalized therapeutic profiles using data from only the individual patient. Without the need for cohort-level data, therapies can be more efficiently tailored to a patient’s genome and, more importantly, the specific effects of the disease on their genome and vice versa.



  • Target critical pathways for drug therapies
  • Development of personalized medicine based on personal genetic mutations/variations
  • Research links between genetic variations and disease pathologies



  • Employs single-subject data analysis by only requiring information about the patient
  • Capable of using as few as two disease-affected cells
  • Considers intra-cellular genetic heterogeneity
  • Accounts for cell-to-cell variations and how these variations affect gene expression in the body as a whole


Licensing Manager: 

Rakhi Gibbons

(520) 626-6695